Mr. Elad Bibi-Aviv reports

SEEGNAL INC. ANNOUNCES TERMINATION OF MARKET MAKING AGREEMENT

Seegnal Inc.'s market-making service agreement dated Sept. 24, 2025, with Generation IACP Inc., previously announced on Sept. 25, 2025, will be terminated, effective March 25, 2026.

About Seegnal Inc.

Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world: adverse drug effects. Seegnal's clinical decision support system introduces a paradigm shift in the approach to this problem by implementing a new elevated patient-centric standard. Seegnal's software-as-a-service technology exclusively integrates at the point of care, unique patient-specific data-like genetics, results of lab tests, ECG, smoking, allergies, food, gender, age and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90 per cent. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Similarly, patients enjoy more tailored medication and improved safety, leading to better quality of life, due to the precision of alerts with up-to-98-per-cent accuracy. Institutions reported a reduction in admissions, medication consumption and ample time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in the State of Israel (where recently the Ministry of Health has adopted Seegnal's patient-specific standard as the new standard in governmental hospitals), the United Arab Emirates, the United Kingdom, the United States and Poland. The platform is currently a standard of care system for over 10,000 clinicians in Israel, used on a daily basis for prescribing medications to their patients.